| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | RRR1; DAPPER3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human DACT3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DACT3抗体的3篇示例参考文献(示例为虚构内容，实际文献需通过学术数据库检索获取)：
---
1. **文献名称**：*DACT3 Suppresses Colorectal Cancer Progression by Inhibiting Wnt/β-Catenin Signaling*
**作者**：Li X, Zhang Y, et al.
**摘要**：本研究利用DACT3特异性抗体，证实DACT3在结直肠癌组织中表达下调，并通过抑制Wnt/β-catenin通路抑制肿瘤侵袭。抗体免疫组化结果显示DACT3与患者预后呈正相关。
2. **文献名称**：*Epigenetic Silencing of DACT3 Promotes Hepatocellular Carcinoma Metastasis*
**作者**：Wang H, Chen J.
**摘要**：通过Western blot和免疫荧光技术，作者发现DACT3在肝癌中因启动子甲基化而表达缺失。使用DACT3抗体进一步验证其通过调控TGF-β信号抑制EMT过程。
3. **文献名称**：*DACT3 as a Biomarker for Chemoresistance in Gastric Cancer*
**作者**：Kim S, Park M.
**摘要**：研究通过DACT3抗体检测胃癌组织样本，发现低表达DACT3的患者对5-FU化疗耐药性增强，机制可能与Wnt通路异常激活相关。
---
实际文献建议通过**PubMed**或**Google Scholar**检索关键词"DACT3 antibody"、"DACT3 expression"或结合具体研究领域(如癌症类型)获取。
DACT3 (Dapper Homolog 3. also known as DPR3) is a member of the Dapper (DACT) protein family, which modulates Wnt signaling and planar cell polarity pathways. Initially identified as a regulator of embryonic development, DACT3 interacts with key signaling components like β-catenin, Dishevelled (Dvl), and TGF-β pathways, influencing cell proliferation, differentiation, and tissue morphogenesis. Structurally, DACT3 contains conserved Dapper homology domains that mediate protein-protein interactions.
In cancer research, DACT3 has gained attention as a potential tumor suppressor. Epigenetic silencing of DACT3 via promoter hypermethylation is frequently observed in malignancies such as colorectal, liver, and gastric cancers. Loss of DACT3 expression correlates with Wnt/β-catenin pathway activation, promoting tumor progression and metastasis. Antibodies targeting DACT3 are essential tools for studying its expression patterns, subcellular localization, and functional roles in both physiological and pathological contexts.
Commercially available DACT3 antibodies are typically developed using immunogens derived from specific epitopes of human DACT3. validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. These reagents help uncover DACT3's diagnostic or prognostic value in cancers and its interplay with signaling networks, offering insights into therapeutic targeting of Wnt-driven malignancies.
×
